# TheraSphere With Durvalumab and Tremelimumab for HCC

Source: https://nuclide.cc/trials/nct05063565/  
Nuclide record `nct05063565` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Durvalumab in hepatocellular carcinoma, run by Boston Scientific Corporation, active and no longer recruiting.

## Summary

TheraSphere With Durvalumab and Tremelimumab for HCC is a phase 2 interventional study registered as NCT05063565 by Boston Scientific Corporation, with 100 participants planned, started 2023-11-03 and due to reach its primary completion in 2027-06. Interventions recorded: TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Also known as: ROWAN
- Tags: ctgov-ingest
- Registry id: NCT05063565
- Phase: 2
- Setting: An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)
- Sponsor: Boston Scientific Corporation
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05063565: https://clinicaltrials.gov/study/NCT05063565

## Connected records

- isotopes: [Yttrium-90](https://nuclide.cc/isotopes/y-90/)
- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/)
- drugs: [Durvalumab](https://nuclide.cc/drugs/durvalumab/)
- companies: [Boston Scientific](https://nuclide.cc/companies/boston-scientific/)
- pairings: [Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma](https://nuclide.cc/pairings/tare-plus-durvalumab-hcc/)

---
JSON: https://nuclide.cc/api/v1/entities/nct05063565.json